Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids.

Next Previous
Search
Trial Profile

A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Repros Therapeutics

    • Most Recent Events

    • 17 Feb 2010 Actual end date (Aug 2009) and actual number of patients (77) added as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 03 Aug 2009 Status changed from recruiting to suspended, according to a Repros Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top